MYOS - MYOS RENS Technology Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.22
-0.02 (-1.61%)
As of 12:47PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.24
Open1.24
Bid1.22 x 1400
Ask1.32 x 2900
Day's Range1.22 - 1.26
52 Week Range1.03 - 2.50
Volume6,091
Avg. Volume31,812
Market Cap9.118M
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateNov 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    MYOS RENS Technology Signs Distribution Agreement With Miller Veterinary Supply East To Bring Innovative MYOS Canine Muscle Formula™ To 6,000+ Veterinary Hospitals

    CEDAR KNOLLS, N.J., Nov. 8, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it has signed a distribution agreement with Miller Veterinary Supply East ("Miller"), which will allow MYOS to sell its MYOS Canine Muscle Formula ("MYOS Canine") in more than 6,000 Veterinary hospitals.

  • PR Newswire6 days ago

    MYOS RENS Technology Announces The Date For The Release Of Third Quarter 2018 Results, Conference Call And Webcast

    CEDAR KNOLLS, N.J., Nov. 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ:MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it will provide financial results for the third quarter of 2018 on Tuesday, November 13 after the market closes. The company will host a conference call on Thursday, November 15, 2018 at 10:30 am ET, at which time MYOS Chief Executive Officer Joseph Mannello will provide commentary on earnings results for the third quarter and provide an update on the business.

  • GlobeNewswire27 days ago

    Investor Expectations to Drive Momentum within Pacific Ethanol, CorVel, Surmodics, Alpha and Omega Semiconductor, MYOS RENS Technology, and Golden Entertainment — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswirelast month

    Centers For Medicare and Medicaid Services Approves Reimbursement For Unique Fortetropin®-Based Enteral Nutrition Formula

    CEDAR KNOLLS, N.J., Oct. 2, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that MYOS Enteral Nutrition Formula, formulated with Fortetropin®, has become eligible for Medicare and Medicaid reimbursement. Specifically, the formula has been approved as an HCPCS B4150 Product after review by the Pricing, Data Analysis, and Coding Contractor for the Centers for Medicare and Medicaid Services ("CMS").  This HCPCS B4150 code is used to describe enteral formulas which are nutritionally complete with intact nutrients, including proteins, fats, carbohydrates, vitamins, and minerals.

  • PR Newswire2 months ago

    MYOS RENS Technology To Exhibit MYOS Canine Muscle Formula™ At The Atlantic Coast Veterinary Conference, October 8-11, 2018

    CEDAR KNOLLS, N.J., Sept. 26, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that MYOS will exhibit at the Atlantic Coast Veterinary Conference in Atlantic City, NJ, from October 8-11, 2018. Featured at the event will be MYOS Canine Muscle Formula™ our first Fortetropin®-based veterinary product.

  • Simply Wall St.2 months ago

    Should You Have MYOS RENS Technology Inc’s (NASDAQ:MYOS) In Your Portfolio?

    If you’re interested in MYOS RENS Technology Inc (NASDAQ:MYOS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stockRead More...

  • Zacks Small Cap Research3 months ago

    MYOS: Yolked Well-Received, MYOS Canine Formula Launched

    MYOS RENS Technology (NASDAQMYOS) reported Q2 '18 financial results and provided a business update. Revenue from Qurr, MYOS' consumer-focused Fortetropin-based products (puddings, powders and shakes) which launched in April 2017, was $56k and $113k in the three and six months ending June 30, 2018. While Qurr continues to be the majority contributor to the company's top-line, accounting for nearly 80% of total revenue through the first half of the year, its proportional contribution will likely moderate as MYOS' new products gain traction.

  • GlobeNewswire3 months ago

    Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications

    NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDF ...

  • PR Newswire3 months ago

    MYOS RENS Technology Reports 49% Increase In Net Revenues In Second Quarter Of 2018

    Increase Driven from Early Success of Yolked™ and MYOS Canine Muscle Formula™ Conference Call to be Held Tomorrow, August 9, 2018, at 11am ET CEDAR KNOLLS, N.J. , Aug. 8, 2018 /PRNewswire/ -- MYOS RENS ...

  • PR Newswire3 months ago

    MYOS RENS Technology Announces The Date For The Release Of Second Quarter And First Half 2018 Results, Conference Call And Webcast

    CEDAR KNOLLS, N.J., Aug. 2, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it will announce financial results for the second quarter and first half of 2018 on Wednesday, August 8 after the market closes. The company will host a conference call on Thursday, August 9, 2018 at 11:00 am ET, at which time MYOS Chief Executive Officer Joseph Mannello will provide commentary on earnings results for the second quarter and first half ended June 30, 2018 and provide updates on its four ongoing clinical studies.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: MYOS RENS Technology and Canopy Growth

    The Dow Jones Industrial Average declined 0.88 percent to close at 24,700.45, while the S&P 500 Index dropped 0.71 percent to close at 2,774.02. The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors.

  • PR Newswire5 months ago

    MYOS RENS Technology Launches Advanced Veterinary Supplement Product For Dogs, Powered By Fortetropin®

    CEDAR KNOLLS, N.J., June 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, today announced the launch of 'MYOS Canine Muscle Formula'.  This is the first product in the Company's new line of advanced veterinary health supplements to support muscle health in dogs, featuring Fortetropin® as the active ingredient. Joseph Mannello, Chief Executive Officer of the Company, stated, "We are excited to be launching our first veterinary health supplement, which helps support muscle health in dogs.

  • Should You Buy MYOS RENS Technology Inc (NASDAQ:MYOS) Now?
    Simply Wall St.6 months ago

    Should You Buy MYOS RENS Technology Inc (NASDAQ:MYOS) Now?

    MYOS RENS Technology Inc (NASDAQ:MYOS), a personal products company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered,Read More...

  • Zacks Small Cap Research6 months ago

    MYOS: Several Development-Related Milestones Upcoming

    MYOS RENS Technology (MYOS) reported Q1 ’18 financial results and provided a business update. While revenue remains muted, that was not unexpected as much of MYOS’ activities continue to be focused on further expanding the evidence surrounding Fortetropin and its beneficial effects in improving muscle health. This evidence-based approach has the potential to pay dividends in the form of more efficient (and successful) commercialization.

  • PR Newswire6 months ago

    MYOS RENS Technology Reports First Quarter Financial Results

    Provides Update on Clinical Studies Programs Conference Call to be Held Tomorrow at 11am ET CEDAR KNOLLS, N.J. , May 9, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") ...

  • PR Newswire6 months ago

    /C O R R E C T I O N -- MYOS RENS Technology Inc./

    In the news release, MYOS RENS Technology Announces the Date for the Release of First Quarter 2018 Results, Conference Call and Webcast, issued 03-May-2018 by MYOS RENS Technology Inc. over PR Newswire, ...

  • ACCESSWIRE7 months ago

    Free Research Report as Lipocine Announced FY17 Financial Results

    Stock Monitor: MYOS RENS Technology Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Lipocine Inc. (NASDAQ: LPCN ). If ...

  • Zacks Small Cap Research7 months ago

    MYOS: A New Product For Sports Nutrition

    MYOS RENS Technology, Inc. (MYOS) announced on April 10, 2018 that it has expanded its product line with the addition of Yolked™. Yolked™ received the Certified for Sport® certification from NSF International. NSF International is an independent organization that provides third-party certification of manufacturing systems and processes as well as for food, water and other products.

  • Was MYOS RENS Technology Inc’s (NASDAQ:MYOS) Earnings Growth Better Than The Industry’s?
    Simply Wall St.7 months ago

    Was MYOS RENS Technology Inc’s (NASDAQ:MYOS) Earnings Growth Better Than The Industry’s?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • PR Newswire7 months ago

    MYOS RENS Technology Introduces New Sports Nutrition Product Line, Yolked™, and Earns Prestigious "Certified For Sport®" Certification From NSF International

    NSF "Certified for Sport®" Certification Further Demonstrates MYOS' Commitment To Providing Safe, Quality Products CEDAR KNOLLS, N.J. , April 10, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ...

  • Zacks Small Cap Research7 months ago

    MYOS: Initiation Report

    Headquartered in Cedar Knolls, NJ, MYOS RENS Technology Inc. (MYOS) is an emerging advanced nutrition and biotherapeutics company. MYOS received patent (U.S. Patent No. 8,815,320 B2) entitled “Process for Producing a Composition Containing Active Follistatin” to cover the proprietary manufacturing of Fortetropin in August 2014 from the USPTO. Fortetropin is a bioactive proteo-lipid complex.

  • PR Newswire7 months ago

    MYOS RENS Technology to Present at the MicroCap Conference April 10 in New York City at the Essex House

    CEDAR KNOLLS, N.J., April 3, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the natural product that helps build lean muscle in conjunction with resistance training, announced that the Company's Chief Executive Officer, Joseph Mannello, will present at the MicroCap Conference on Tuesday, April 10th at 12:30 p.m. Eastern Time at the Essex House in New York City. Mr. Mannello will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. "We are excited about the opportunity to meet with investors to discuss our recent business developments," said Mr. Mannello.

  • PR Newswire8 months ago

    MYOS RENS Technology CEO Joseph Mannello Provides Comments On Operational And Financial Results For Fiscal Year 2017

    CEDAR KNOLLS, N.J., March 28, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, a proprietary  ingredient that helps build lean muscle in conjunction with resistance training, presents comments from Chief Executive Officer, Joseph Mannello, on the operational and financial results for the year ended December 31, 2017. "I want to start by saying a few words about our financial results for 2017.